Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
Jaewon Choi(BioNTech (United States)), Vikram R. Juneja(Takara (United States)), Marit M. van Buuren(The Netherlands Cancer Institute), Jennifer G. Abelin(Broad Institute), Christopher D. McGann(BioNTech (United States)), Daniel Rothenberg(Brighton Hospital), Divya Lenkala(BioNTech (United States)), Paul Turcott(BioNTech (United States)), Jessica Kohler(BioNTech (United States)), Jared L. Dietze(BioNTech (United States)), Terri A. Addona(BioNTech (United States)), Scott P. Goulding(BioNTech (United States)), Antoine Boudot(BioNTech (United States)), Kendra C. Foley(BioNTech (United States)), Richard B. Gaynor(BioNTech (United States)), Michael S. Rooney(BioNTech (United States)), John Srouji(BioNTech (United States)), Brandon Conn(BioNTech (United States))
Cited by 65
Related Papers
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
|Journal of Clinical Investigation|2001|1.6k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
|The Journal of Experimental Medicine|2017|872
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799